Oct, 13 2016 05:15 JST

Source: Eisai

Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide

Japan's First Food with Function Claims Drink Containing Ceramide
- "Drink" to Counter Dry Skin -

TOKYO, Oct, 13 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch its first food with function claims Chocola BB Rich Ceramide (Notification number: B60) in drugstores, pharmacies and convenience stores throughout Japan on Monday, October 17. The product is Japan's first drink that is a type of food with function claims containing glucosylceramide derived from rice.(1)

Ceramide is a component of the stratum corneum of the epidermis layer of human skin. Normally, ceramide fills the spaces between cells in the corneum of the skin, and plays a role in restraining the loss of moisture to the outside as well as protecting the skin from external stimuli such as ultraviolet rays. Therefore, a lack of ceramide advances transpiration of skin moisture, potentially leading to dryness in the skin. Since ceramide levels decline with age, it is important to appropriate replenish ceramide to counter dryness.

Containing glucosylceramide as its active component to make it harder for moisture to escape from the skin,(2) Chocola BB Rich Ceramide is a product that you can drink to counter dry skin. Furthermore, in addition to ceramide, the drink also contains collagen and hyaluronic acid which are known for their beauty properties, and is recommended for people who are highly beauty conscious. Chocola BB Rich Ceramide has a delicious, easy to drink pear flavor, is low in calories (8.2 kcal), and with zero caffeine, can be safely consumed before sleep.

Chocola BB Rich Ceramide is now available nationwide through a wide range of retail outlets including drug stores, pharmacies, convenience stores and Eisai's internet retailing site.

Centered around the signature OTC product Chocola BB Plus (Third-class OTC drug) for the relief of skin trouble, acne and mouth ulcers, Eisai has been expanding the Chocola BB brand to suit the needs and lifestyles of its customers such as Chocola BB Royal 2 (quasi-drug), a nutritional drink for invigoration when physically fatigued, Chocola BB Joma, a soft drink that contains vitamin B6 (Food with Nutrient Function Claims), and Chocola BB Mouth Ulcer Repair Shot (Third-class OTC drug), an oral care spray launched in August.

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.

(1) Chocola BB Rich Ceramide was accepted by the Consumer Affairs Agency as Japan's first food with functional claims drink that contains glucosylceramide derived from rice.

(2) For information such as the scientific basis of Chocola BB Rich Ceramide, please refer to the Consumer Affairs Agency's home page:
https://www.fld.caa.go.jp/caaks/cssc02/?recordSeq=41604270150104 (in Japanese only)

About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Public Relations Department,
Eisai Co., Ltd.
Source: Eisai
Sectors: Biotech & Pharm

Copyright ©2016 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016
October 12 2016 22:54 JST
Exclusive Licensing Agreement for In-house Developed Monoclonal Antibody Farletuzumab in Latin America Concluded with Eurofarma Laboratorios S.A.
October 04 2016 13:49 JST
Launch of Uritos Tablets for Overactive Bladder in Thailand
October 04 2016 13:35 JST
BELVIQ XR - a New Once-daily Formulation of BELVIQ for Chronic Weight Management Now Available in the United States
October 04 2016 09:03 JST
Eisai to Initiate Phase III Clinical Study of Anti-Cancer Agent Lenvatinib as Potential First-Line Therapy for Advanced Renal Cell Carcinoma
September 30 2016 09:21 JST
Eisai to Present Latest Data on Lenvatinib and Eribulin at ESMO Congress 2016
September 29 2016 08:15 JST
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis
September 28 2016 15:23 JST
Eisai Commences Provision of "EMILY" Smartphone App to Support Living with Epilepsy in Japan
September 28 2016 14:48 JST
Eisai Submits Supplemental Application for Partial Label Change for Antiepileptic Drug Fycompa
September 28 2016 09:46 JST
Eisai Receives License for New Indication for Anticancer Agent Kisplyx (Lenvatinib Mesylate) for Treatment of Advanced Renal Cell Carcinoma
September 15 2016 10:29 JST
More Press release >>

Latest Press Release

More Latest Release >>